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Summary. Inhibitors are a rare but serious complication
of treatment of patients with haemophilia. Phase III
clinical trials enrol too few patients to adequately assess
new product inhibitor risk. This project explores the
feasibility of using a public health surveillance system to
conduct national surveillance for inhibitors. Staff at 17
U.S. haemophilia treatment centres (HTC) enrolled
patients with haemophilia A and B into this prospective
study. HTC staff provided detailed historic data on
product use and inhibitors at baseline, and postenrolment
patients provided monthly detailed infusion logs. A
central laboratory performed inhibitor tests on blood
specimens that were collected at baseline, annually, prior
to any planned product switch or when clinically
indicated. The central laboratory also performed
genotyping of all enrolled patients. From January 2006
through June 2012, 1163 patients were enrolled and
followed up for 3329 person-years. A total of 3048
inhibitor tests were performed and 23 new factor VIII
inhibitors were identified, 61% of which were not
clinically apparent. Infusion logs were submitted for
113 205 exposure days. Genotyping revealed 431
distinct mutations causing haemophilia, 151 of which
had not previously been reported elsewhere in the world.
This study provided critical information about the
practical issues that must be addressed to successfully
implement national inhibitor surveillance. Centralized
testing with routine monitoring and confirmation of
locally identified inhibitors will provide valid and
representative data with which to evaluate inhibitor
incidence and prevalence, monitor trends in occurrence
rates and identify potential inhibitor outbreaks associated
with products.
Keywords: haemophilia, haemophilia inhibitor, surveil-
lance
Introduction
Persons with haemophilia are deficient in a protein
that is necessary for normal blood clotting. As many
as one-third will develop an antibody (inhibitor) to
the intravenous antihaemophilic factor products given
to stop or prevent a bleeding episode [1]. Most inhibi-
tors develop during the first few infusions with factor
which, especially among those with severe haemo-
philia, typically occur before the age of 2 years.
Although most of these inhibitors are transient and
will resolve, 5–7% of the haemophilia population
have a clinically significant long-term inhibitor [1]. An
inhibitor renders the treatment product ineffective in
controlling bleeding. The public health costs associ-
ated with inhibitors are staggering. People with hae-
mophilia and an inhibitor are twice as likely to be
hospitalized for a bleeding complication [2]. The costs
of treatment and hospital care have been reported to
be 2–10 times greater for those with inhibitors, com-
pared to those without an inhibitor [3–5].
In November 2003, the U.S. Food and Drug Admin-
istration (FDA) held a workshop on factor VIII (FVIII)
inhibitors [6]. The purpose of the workshop was to
convene a group of experts to advise the FDA on how
to design studies to objectively evaluate the risk of
either new treatment products or products that have
undergone significant manufacturing changes to
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induce inhibitor formation in previously treated
patients. Subsequently, the European Medicines
Agency (EMA) held a similar meeting and produced a
report of its findings in 2006 [7]. Recognizing that
clinical trials alone were inadequate to fully assess a
product’s immunogenicity, the EMA recommended
long-term data collection through postmarket surveil-
lance or registries. The recommendations further stip-
ulated that studies of inhibitors should prospectively
collect data on all treatment exposures and include
details such as age at treatment onset, reasons and
intensity of treatment, product switching and other
environmental variables, as well as data on genetic fac-
tors such as haemophilia severity, gene mutation, family
inhibitor history and ethnicity. Finally, the agencies rec-
ommended that monitoring for inhibitors should
involve clinical and laboratory study using standardized
methods with a high degree of quality control.
In 1998, a public health surveillance system called
the Universal Data Collection (UDC) system was
established by the Centers for Disease Control and
Prevention (CDC) in more than 125 federally sup-
ported specialized haemophilia treatment centres
(HTCs) in the United States [8]. Although the system
was not specifically designed to study inhibitors, data
from this system were used in a previous study to esti-
mate the incidence of inhibitors in previously treated
patients [9].
The purpose of this study was to determine the fea-
sibility of incorporating the EMA and FDA guidelines
into such a surveillance programme. Specifically, the
study was designed to evaluate (i) the ability to pro-
spectively collect complete and accurate records of
factor infusions, (ii) methodologies to perform gene
sequencing on a large number of patients and (iii)
methodologies to ship and accurately test blood speci-
mens for inhibitors in a central laboratory.
Materials and methods
Site selection
Haemophilia treatment centres already participating in
the UDC surveillance programme were eligible to par-
ticipate. Nine sites were originally selected based on
willingness to participate, representativeness with
regard to geographic catchment area, number of
patients served (a mixture of small and large centres
was desired), ability to hire a dedicated coordinator
and the use of an electronic medical record system
(Lab TrackerTM; Ground Zero Software, Inc., San
Francisco, CA, USA) developed specifically to record
treatment-related data. Eight additional sites were
later added, three to augment the sample size of chil-
dren less than 2 years of age and five to increase the
number of Black and Hispanic participants. CDC pro-
vided the study protocol and data collection instru-
ments and the project was approved by Investigational
Review Boards both at CDC and at each participating
institution.
Participant recruitment
All patients with haemophilia A (HA) and haemo-
philia B (HB) participating in the UDC programme
were initially eligible for participation. After August
2009, patients with a previous history of an inhibitor
were excluded. Patients were recruited during HTC
visits and all participants (or parents of minor chil-
dren) signed an IRB-approved informed consent. Indi-
viduals using electronic infusion log tools were asked
for permission to access these data for the study.
Data collection
Data collected at enrolment included month and year
of birth, ethnicity, haemophilia type and severity and
the number of lifetime exposure days to factor concen-
trates based on participants’ medical records, clinic
records and recall. If the patient had a history of an
inhibitor, additional data were collected on the highest
titre result and most recent titre result based on local
testing and on the use of immune tolerance therapy
and adjunctive medications.
After enrolment, the following data about each infu-
sion with factor concentrates were collected: date and
time of infusion, location of infusion (treatment centre
setting vs. non-treatment centre setting), product
name, vial lot number(s) and corresponding vial
amount(s) and reason for infusion. If the infusion was
to treat a bleed, the time between bleed and infusion,
cause of bleed (spontaneous vs. trauma) and bleed
location was collected. If the infusion was for a medi-
cal procedure/surgery, the type of procedure and date
performed were collected.
Data were also collected at each blood specimen
draw and included the date and time, the date of the
most recent treatment product infusion, product
name, amount infused and the reason for the draw.
If the reason for the blood draw was a product
switch, additional data including the type of product
switch and the reason for the product switch were
collected.
Specimen collection
Blood specimens were collected at enrolment into the
study, annually, prior to any planned treatment prod-
uct switch, and at clinical indication of an inhibitor
(determined by the attending haematologist); a second
sample was requested to confirm a positive specimen.
Blood was collected into 3.2% sodium citrate and
centrifuged at 16009 g for 20 min at 4°C, followed
by repeat centrifugation of the separated plasma at
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16009 g for 20 min at 4°C. Separated plasma samples
were shipped to CDC overnight on cold packs. The
remaining cell pellet was also sent on cold packs to
CDC to be used for haemophilia gene mutation test-
ing. At CDC, the plasma samples were aliquoted and
stored at 70°C. During the study, the plasma speci-
mens from 50 patients were split; half were sent as
described above, and the other half were frozen at
70°C then shipped overnight to CDC on dry ice.
Inhibitor testing
FVIII inhibitors were measured at CDC by a modifica-
tion of the Nijmegen-Bethesda method described else-
where [10]. Briefly, plasma specimens were heated to
56°C for 30 min and centrifuged at 27009 g for
5 min at room temperature. The supernatant was
tested as described by Verbruggen et al. [11] using
imidazole-buffered normal pool plasma (Precision Bio-
logic, Dartmouth, NS, Canada) and dilution in haem-
ophilic plasma (George King, Overland Park, KS,
USA). FIX inhibitors were measured similarly.
Genotyping
Sequencing of the 5′ and 3′ untranslated regions all
exons, and all intron–exon junction regions of the
FVIII gene (F8) and the FIX gene (F9) was carried out
in forward and reverse directions using an automated
analyser (3730 DNA Analyzer; Applied Biosystems,
Carlsbad, CA, USA) and the VariantSEQrTM protocol.
Data were analysed with SeqScape. Intron 22 and
intron 1 inversions in F8 were detected by polymerase
chain reaction [12,13]. Multiplex ligation-dependent
probe amplification (MLPA) was performed using
SALSA MLPA Kits P178-A1Factor VIII and P207-C1
F9 (MRC Holland, Amsterdam, the Netherlands).
Infusion log collection
Local site coordinators provided participants with the
CDC infusion log data instrument and discussed with
enrolees other options available to keep the infusion
data such as retaining factor product box-tops, paper
calendars, site-provided data forms, electronic infu-
sion log tools (e.g. Advoy, EZ Log) or utilizing
formatted Microsoft Excel spreadsheets. Adherence to
the collection of infusion data, based on submission
of infusion logs or patient report of no infusions,
was determined for each participant on a monthly
basis.
Data analysis
Descriptive statistics were used to describe the demo-
graphic and clinical characteristics of the study popu-
lation and follow-up time in the study. Correlations
between inhibitor test results on samples sent to CDC
on cold packs vs. dry ice were examined using the
Spearman correlation coefficient. Percent compliance
was calculated by dividing the number of months that
a patient submitted infusion data by the total number
of months he was on study and multiplied by 100.
Comparisons of means used t-tests and comparisons
of means adjusted for other variables utilized general
linear regression. All statistical analyses were per-
formed using SAS 9.3 (SAS Institute, Cary, NC, USA).
Differences in measures with P ≤ 0.05 were consid-
ered statistically significant.
Results
From January 1, 2006 until June 31, 2012, staff at 17
HTCs enrolled 1163 patients with the characteristics
shown in Table 1. Subjects ranged in age from
2 months to 84.4 years with a mean of 20.4 years
(median = 15.1 years) at enrolment. The distributions
of haemophilia type and severity were similar to those
seen in population studies, and 129 (11.1%) had a
history of a previous inhibitor according to local clini-
cal records. One-fourth of the subjects had fewer than
20 exposure days to factor concentrates and about
60% had been exposed to product more than
100 days in their lifetime at enrolment into the study.
The total subject follow-up time was 3329 person-
years.
Table 1. Characteristics of people with haemophilia enrolled in the study.
Total
Haemophilia
A
Haemophilia
B
n % n % n %
Total enrolled 1163 950 81.7 213 18.3
Severity
Mild 250 21.5 199 20.9 51 23.9
Moderate 233 20.0 146 15.4 87 40.9
Severe 680 58.5 605 63.7 75 35.2
Age at enrolment
<2 years 52 4.5 49 5.1 3 1.4
2–9 years 361 31.1 298 31.4 63 29.6
10–19 years 301 25.9 242 25.5 59 27.7
20–29 years 183 15.7 151 15.9 32 15.0
30–45 years 133 11.4 113 11.9 20 9.4
>45 years 133 11.4 97 10.2 36 16.9
Sex
Male 1161 99.8 948 99.8 213 100.0
Female 2 0.2 2 0.2 0 0.0
Race
White 946 81.3 767 80.7 179 84.0
Black 86 7.4 69 7.3 17 8.0
Hispanic 74 6.4 67 7.0 7 3.3
Asian 21 1.8 17 1.8 4 1.9
Other 36 3.1 30 3.2 6 2.8
Prior exposure days
0 37 3.2 32 3.4 5 2.3
1–20 232 19.9 162 17.1 70 32.9
21–100 158 13.6 119 12.5 39 18.3
101–150 75 6.4 63 6.6 12 5.6
>150 659 56.7 572 60.2 87 40.9
Proportions do not all sum to 100% due to missing data.
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Inhibitor testing
Modified shipping conditions were tested on 50 speci-
mens with inhibitor titres ranging from 0 to 900. Split
samples shipped either on cold packs or frozen
showed excellent correlation (r = 0.998). The cold
pack method was chosen to simplify specimen han-
dling. Initial tests of 228 frozen specimens from severe
HA patients showed that 126 (55%) had measurable
FVIII activity; all were from patients reported to have
been treated with FVIII-containing products within
72 h of blood collection. A heating step was intro-
duced to eliminate residual FVIII [10]. Based on the
results on 710 HA specimens collected at enrolment,
the reference range for a positive CDC test result was
set at ≥0.5 Nijmegen-Bethesda Units (NBU) for FVIII
[10]. Among 160 FIX inhibitor tests performed, no
HB patient without a previous history of inhibitor had
a titre >0.2 NBU. A positive CDC test result for FIX
was set at ≥0.3 NBU [10].
During the study period, a total of 3,048 inhibitor
tests were completed. The baseline test at enrolment
accounted for 38.2% (n = 1163), the annual inhibitor
test 59.5% (n = 1813), anticipated product switch
testing 1.3% (n = 40) and tests for clinical indication
accounted for 1% (n = 32) of the total. The sites were
able to obtain 68% of the expected 2680 annual spec-
imens based on the time on study.
We detected an inhibitor titre above the cut-off
value in 23 HA patients either at enrolment or during
follow-up (Table 2). Of the nine patients with ele-
vated inhibitor titres detected at enrolment, none had
any overt clinical signs or symptoms, 89% had more
than 20 days of lifetime exposure to concentrates and
44% were over the age of 5 years. Among those with
an elevated inhibitor titre detected during follow-up,
36% had no clinical indication. Compared to those
with elevated titres detected at enrolment, a greater
proportion of patients with elevated titres detected
during follow-up had peak titres >1 NBU. Of those
with newly elevated inhibitor titres detected, 78% had
high-risk mutations, and overall 61% were not
recognized by HTC staff as having an inhibitor prior
to the CDC testing. No newly elevated inhibitor titres
were detected in HB patients.
Genotyping
Mutation analysis was performed on specimens
obtained from 902 subjects with HA and 214 subjects
with HB. A total of 342 distinct F8 mutations were
identified, of which 140 had not previously been
reported (Fig. 1). Among HB patients, 89 distinct F9
mutations were found, 11 of which had not been
reported. Mutation type frequency by severity is
shown in Figs 2 and 3. In severe HA, the most com-
mon mutations were intron 22 inversions, occurring
in 40.6% of subjects. Missense mutations predomi-
nated in patients with moderate and mild HA and in
all severities of HB.
Infusion log collection
Infusion data were collected from 976 patients
(83.9%) during the study period. Of those, 180
(18.4%) reported receiving no infusions during their
follow-up time. Data on infusions were collected from
the remaining 796 participants totalling 113 205
exposure days. Recombinant products were the most
utilized product type, as reported by participants
(Table 3).
The overall mean compliance with reporting infu-
sions by participants was 63.0%. HTC, age at enrol-
ment and disease severity were each significantly
associated with participant compliance with reporting
(P < 0.0001). Compliance with reporting varied across
participating HTCs from 51% to 94% (Fig. 4). Partic-
ipants aged 20–29 years at enrolment were the least
likely to keep and/or submit infusion logs (Fig. 5).
After adjusting for HTC and age, compliance rates
differed significantly by severity; 82.3% mild, 71.7%
moderate and 53.0% severe (P < 0.0001).
Discussion
In the United States, the FDA has established a passive
drug safety monitoring system based on voluntary
reports from physicians to collect adverse event
reports on drugs. It is recognized that adverse events
are underreported to this system due to a variety of
reasons including lack of evidence of causality, insuffi-
cient time for reporting or lack of knowledge about
reporting criteria or procedures [14,15]. Anecdotal
evidence suggests that inhibitors are likely to be
underrepresented in this monitoring system as many
care providers consider inhibitors to be a known treat-
ment side effect rather than an adverse event. In addi-
tion, not all providers routinely test for inhibitors. For
example, among the nearly 7000 patients with severe
Table 2. Inhibitor titre elevations detected at enrolment and during the
study according to selected demographic and clinical characteristics.
Detected
at enrolment
(%)
Detected
during study
follow-up (%)
Total
detected
(%)
Non-severe 3/9 (33) 5/14 (36) 8/23 (35)
Age > 5 years 4/9 (44) 6/14 (43) 10/23 (43)
Exposure days > 150 3/9 (33) 2/14 (14) 5/23 (22)
Exposure days > 20 8/9 (89) 5/14 (36) 13/23 (57)
White non-hispanic ethnicity 7/9 (78) 10/14 (71) 17/23 (74)
High-risk mutation 8/9 (89) 10/14 (71) 18/23 (78)
Initial titre > 1.0 NBU 4/9 (44) 11/14 (79) 15/23 (65)
Peak titre > 1.0 NBU 4/9 (44) 11/14 (79) 15/23 (65)
Peak titre > 5.0 NBU 2/9 (22) 5/14 (36) 7/23 (30)
No clinical indication 9/9 (100) 5/14 (36) 14/23 (61)
NBU, Nijmegen Bethesda Units.
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Fig. 1. Distribution and relative number of mutations associated with mild, moderate and severe haemophilia A across F8 by mutation type.
Fig. 2. Distribution of factor VIII mutation types by severity identified among participants with haemophilia A in the study.
Fig. 3. Distribution of factor IX mutation types by severity identified among participants with haemophilia B in the study.
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haemophilia who had a comprehensive visit to an
HTC during 2006–2010, 46% had an inhibitor titre
measured (unpublished CDC data).
As a result, the occurrence of inhibitors in the US
haemophilia population is not known. Public health
planning and resource allocation for efforts to prevent
or minimize the impact of inhibitors are hampered by
the lack of information on the burden of this serious
complication of haemophilia care. At the least, data
on occurrence are needed to identify target popula-
tions, track trends in rates over time and identify ‘out-
breaks’ of inhibitors [16].
The purpose of this study was to determine whether
we could enhance data collection, as part of a
national public health surveillance system providing
the largest sample size possible in the United States, to
achieve reliable rates of occurrence and to facilitate
research into the causes of inhibitors in a way that
minimizes the limitations of previous studies. We were
able to implement centralized testing for inhibitors by
utilizing a simple method of sample collection and
shipping and high-throughput technologies to make
the testing efficient and cost saving. Our methodology
also allowed us to test patients who had recently
infused factor which is a barrier to the testing
performed in most local laboratories. Data from large
numbers of tests were used to develop methods that
were consistent, reliable and reproducible and to set a
cut-off for a positive inhibitor with the CDC test.
Although collection of annual blood specimens for
inhibitor testing was part of the study protocol,
achieving compliance was challenging. The frequency
of inhibitor testing for clinical management varied
widely across HTCs. Annual testing was particularly
challenging for participants with mild and moderate
haemophilia because they were less likely to visit the
clinic annually. Another barrier to regular inhibitor
screening outside this study could be the cost, which
may not be reimbursed by payers in the absence of
clinical evidence of an inhibitor. Despite these chal-
lenges we were able to achieve nearly 70% compli-
ance with the specimen submission requirements for
the study.
Although inhibitors are an adverse event that hae-
matologists expect some patients will experience, early
identification through routine, regular inhibitor screen-
ing could play a role in decreasing the duration and
increasing the success of treatment of an inhibitor [17]
and, thereby, lower the cost and morbidity associated
with inhibitor development. In this study, we found a
surprising number of cases that had gone unrecog-
nized by their care providers including one patient
who had a 54 NBU inhibitor titre. Had we been test-
ing only ‘high risk’ patients we would have missed a
substantial proportion of these new cases: one-third
had non-severe disease and one-quarter had greater
than 150 exposure days. We believe that these findings
provide justification for the need for in-depth monitor-
ing for inhibitors on a regular basis. One-third of the
elevated titres identified by our testing measured
<1 NBU. The clinical relevance of these low level titre
elevations is not completely understood. It is recog-
nized that some patients on prophylaxis require larger
doses of factor than expected to prevent bleeding epi-
sodes and it is possible that such low-level elevations
play a role in this phenomenon. Further study of this
issue is needed.
Another important aspect of this project was the
development of high-throughput mutation testing. In
the United States, fewer than 15% of haemophilia
patients have been genotyped (unpublished CDC
data). At 186 000 base pairs, F8 is one of the largest
Table 3. Distribution of the factor product type utilization reported by
participants according to inhibitor history.
Product type
No history
of an inhibitor
(N = 695)
History of
an inhibitor
(N = 101)
Recombinant 625 70
Plasma derived 39 2
Plasma derived with VWF 3 0
Recombinant & plasma derived 8 1
Recombinant & plasma
derived with VWF
6 0
Plasma derived & plasma
derived with VWF
1 0
Bypass/prothrombin complex 1 11
Bypass/prothrombin complex &
recombinant
4 9
Bypass/prothrombin complex &
plasma derived
1 0
Bypass/prothrombin complex &
plasma derived with VWF
0 3
Bypass/prothrombin complex &
recombinant & plasma derived
with VWF
1 5
Other 6 0
VWF, von Willebrand factor.
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Fig. 4. Mean patient compliance to reporting infusions by haemophilia
treatment center (HTC) site. Mean values are adjusted for haemophilia
treatment center and patient haemophilia severity using analysis of
variance. HTC, haemophilia treatment center.
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human genes and over 2,500 unique mutations have
been identified [18]. Few laboratories offer the com-
plete testing profile and its cost has been high.
Sequencing of the smaller F9 gene is more widely
available, but HB is much less common. Yet, it is
important to note that 78% of the patients identified
with a newly elevated inhibitor test in this study had
high-risk mutations.
Haemophilia treatment centre collection of detailed
patient recorded data on infusions proved highly feasi-
ble. There were two main local site components that
improved reporting compliance among participants.
HTCs that were routinely collecting infusion logs as
part of clinical management prior to participating in
the study were able to maintain high compliance rates.
In addition, local study coordinators who regularly
contacted participants, who built relationships with
participants and who offered flexibility in the method
patients used to record data achieved high compliance
rates. Despite the feasibility of prospectively collecting
comprehensive product exposure data on study, we
believe that a satisfactory level of compliance to
recording infusions is unlikely to be achievable on a
national scale without more widespread use of infu-
sion data for clinical management.
Conclusion
Based on these findings, implementation of national
inhibitor surveillance in the United States is feasible
with some modifications to the components of this
study. Routine centralized inhibitor screening using a
validated testing methodology will ensure standardized
test results and facilitate complete monitoring of inhibi-
tor rates in a large population of patients over time
which would facilitate analyses of trends. Such analyses
will be important as new products are developed and
postmarket surveillance is required to evaluate the
long-term safety of these products. Recent meetings of
stakeholders have confirmed the importance of inhibi-
tors as a critical public health issue for the haemophilia
community. This study has provided essential informa-
tion on how a surveillance system could be imple-
mented using the existing CDC surveillance model.
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